
Extended INDIGO and FIREFLY-1 results presented at SNO 2026 put seizure burden during vorasidenib therapy and time off tovorafenib in pediatric low-grade glioma into focus.
Expiring patents of brand name drugs have paved the way for increased competition in the year ahead.
The year 2016 is shaping up to be a big year for FDA drug approvals, with an estimated $20 billion targeted for generic treatments,
Numerous name brand drugs such as Gleevec, Crestor, Benicar and Benicar HCT, Seroquel XR, and Zetia have expiring patents that pave the way for new competition to enter the market.
Below are the top drugs in the pipeline either expected to be approved or have the chance to gain approval this year.






